logo-loader

Swiss broad label approval 'a further endorsement' of Shield's Feraccru drug

Published: 06:53 29 Apr 2019 EDT

Shield Therapeutics PLC’s (LON:STX) chief executive Carl Sterritt elaborates on the decision by Switzerland’s medical authorities to give approval for its Feraccru iron deficiency drug for all adults with iron deficiency.

He says they'll now be able to market the drug to any adult, whether or not they have been diagnosed with anaemia.

The news comes ahead of the FDA’s decision on whether to grant marketing approval for Feraccru in the US which is due 27 July 2019.

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 10/03/2023